Author:
Chen Jin,Liu Yu,Cai Hong,Zheng Wenfa
Abstract
Abstract
Background and objectives
The aim of this study is to assess and examine the risk variables associated with pulmonary infections in non-small cell lung cancer (NSCLC) and to offer evidence-based recommendations for clinical prophylaxis.
Methods
Up to December 2023, database such as CNKI, Wanfang, VIP Chinese Science and Technology Journals, Chinese Biomedical, Pubmed, Web of science, and the Cochrane library were searched in order to find randomized controlled trials pertaining to non-small cell lung cancer complicated by pulmonary infection. The NOS scale was utilized to assess the quality of the included research, and the Q test findings were utilized to ascertain the degree of heterogeneity among the studies.
Results
After retrieving 957 studies in total, 10 literatures were ultimately included for additional analysis. Diabetes mellitus [OR, 2.89; 95% CI: 1.85–4.52; P < 0.00001)] hypoalbuminemia, radiotherapy [OR, 0.43; 95% CI: 1.89–4.07; P < 0.00001], and surgical duration exceeding 180 min [OR,1.10 (1.10 ~ 5.38); P = 0.03] were found to be risk factors for lung infection. Nevertheless, in NSCLC patients, pulmonary infection was not significantly correlated with factors such as age [OR, -0.16 (-0.96 ~ 0.64); P = 0.69], sex [OR, 1.08 (0.77 ~ 1.51); P = 0.66], smoking [OR, 1.10 (0.61 ~ 2.00); P = 0.75], adenocarcinoma [OR,1.10 (0.55 ~ 2.22); P = 0.79], OR, 1.08; 95% CI: 0.77–1.51; P = 0.66], TNMIII-IV stages [OR, 1.62; 95% CI: 0.96–2.75; P = 0.07], and hypertension [1.01(0.76 ~ 1.34); P = 0.94].
Conclusion
Diabetes mellitus, radiation therapy, and longer than 180-minute surgeries are risk factors for lung infection in NSCLC patients. The incidence of lung infection can be reduced by quickly identifying these risk factors and putting preventive measures in place.
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Kanazu M, Edahiro R, Krebe H, Nishida K, Ishijima M, Uenami T, Akazawa Y, Yano Y, Yamaguchi T, Mori M. Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: a case series. Thorac Cancer. 2018;9(12):1782–7.
2. Gill RR, Murphy DJ, Kravets S, Sholl LM, Janne PA, Johnson BE. Success of genomic profiling of non-small cell lung cancer biopsies obtained by trans-thoracic percutaneous needle biopsy. J Surg Oncol. 2018;118(7):1170–7.
3. Eladawei GE, Abdellatif RM, El-Taher SM. Local consolidation Therapy versus Observation for Oligometastatic non Small Cell Lung Cancer patients: Phase II Randomized Trial. J Cancer Therapy. 2018;09(11):925–40.
4. Zhang Q, Liu S, Wang L, Lang Y. Relationship between postoperative pulmonary infection and pathogenic airway colonizing bacteria in patients with non-small cell lung cancer. Med Pharm J Chin People’s Liberation Army. 2020;32(9):13–7.
5. Pan Y, Wang H, Rao M, Zhang M, Dong J, Lu Y. Analysis of risk factors of lung cancer complicated with venous thromboembolism. J Clin Pulmonary Med. 2019;24(6):1091–4.